Profile: Athersys Inc (ATHX.OQ)
10 Dec 2013
Athersys Inc., incorporated on October 24, 1995, is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials. The Company’s clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The Company is also engaged in the development of small molecule therapies to treat obesity and other conditions. During 2011, the Company is focused on the development of potent, highly selective compounds that act through stimulation of a specific receptor in the brain that controls appetite, the 5HT2c serotonin receptor.
Regenerative Medicine Programs
The Company is developing a non-embryonic, allogeneic stem cell product candidate, MultiStem. The applications of MultiStem, include the treatment of cardiovascular disease, neurological disease or injury and conditions involving the immune system, including autoimmune disease and other conditions. During 2011, the Company had open Investigational New Drug applications (INDs), for the study of MultiStem in distinct clinical indications. MultiStem is a biologic product that is manufactured from human stem cells obtained from adult bone marrow. The product consists of a special class of human stem cells that have the ability to express a range of therapeutically relevant proteins and other factors, as well as form multiple cell types. Another focus of the Company's regenerative medicine program is the use of MultiStem for the treatment of neurological injury as a result of acute or chronic conditions.
During 2011, the Company is developing pharmaceutical treatments for obesity, which is a compound designed to act by stimulating a receptor in the brain that regulates appetite and food intake, the 5HT2c receptor. The role of this receptor in regulating food intake is well understood in both animal models and humans. The Company initiated a drug development program focused on creating potent and selective compounds that stimulate the 5HT2c receptor, but that avoid the 5HT2b receptor and other receptors, such as 5HT2a.
Other Small Molecule Programs & Key Technologies
In addition to the Company's product development programs, the Company developed its random activation of gene expression (RAGE) technology that provides the Company with the ability to produce human cell lines. The Company's RAGE technology is not a therapeutic product, it is a commercial technology that the Company has successfully applied for the benefit of its partners and that the Company has also used for its own internal drugs development programs.
The Company competes with Osiris Therapeutics, Inc., Mesoblast Limited, Aastrom Biosciences, Stem Cells Inc., Johnson & Johnson, Celgene Corporation, Celgene, Advanced Cell Technology, Inc., CRYO-CELL International, Inc., Pluristem Therapeutics Inc., Pluristem, and Cytori Therapeutics, Inc., Cytori, Gamida Cell Ltd., Plureon Corporation, NeoStem, Inc. and Tigenix NV., Bristol-Myers Squibb, Merck & Co., Inc., Roche, Sanofi U.S., Sanofi, GlaxoSmithKline plc, GlaxoSmithKline, Eli Lilly and Company, Arena Pharmaceuticals, Inc., Arena Pharmaceuticals, Orexigen Therapeutics, Inc., Vivus, Inc., Vivus, Neurosearch, Amgen Inc., Amgen, Regeneron Pharmaceuticals, Inc., Nastech Pharmaceutical Company, Alizyme plc, Amylin Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Shionogi & Co., Ltd., Metabolic Pharmaceuticals Limited, Kyorin Pharmaceutical Co., Ltd. and Pfizer Inc.
3201 Carnegie Avenue
CLEVELAND OH 44115-2634